Real Life Data for Otezla Evidence: Assessing Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
Phase of Trial: Phase IV
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms REALIZE
- Sponsors Celgene Corporation
- 19 Aug 2019 Planned End Date changed from 24 Sep 2020 to 24 Mar 2021.
- 08 Feb 2019 Planned End Date changed from 26 Sep 2020 to 24 Sep 2020.
- 08 Feb 2019 Planned primary completion date changed from 26 Mar 2019 to 24 Mar 2020.